Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biotechnology healthcare
| Biotechnology healthcare |
| Pubbl/distr/stampa | Yardley, PA, : BioCommunications, 2004-[2012] |
| Disciplina | 660.6 |
| Soggetto topico |
Biotechnology
Biopharmaceutics Medical technology Medicine |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Formato | Materiale a stampa  |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996216694403316 |
| Yardley, PA, : BioCommunications, 2004-[2012] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals [[electronic resource] /] / by John Geigert
| The Challenge of CMC Regulatory Compliance for Biopharmaceuticals [[electronic resource] /] / by John Geigert |
| Autore | Geigert John |
| Edizione | [4th ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (597 pages) |
| Disciplina | 615/.19 |
| Soggetto topico |
Biologicals
Biopharmaceutics Pharmaceutical chemistry Pharmacy Biologics Pharmaceutics |
| ISBN | 3-031-31909-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Biopharmaceutical Landscape -- Regulatory Pathways Impacting Biopharmaceuticals -- Differences in CMC Regulatory Compliance: Biopharmaceuticals Versus Chemical Drugs -- Risk Management of the Minimum CMC Regulatory Compliance Continuum -- Ever-Present Threat of Adventitious Agent Contamination -- Starting Materials for Manufacturing the Biopharmaceutical Drug Substance -- Upstream Production of the Biopharmaceutical Drug Substance -- Downstream Purification of the Biopharmaceutical Drug Substance -- Manufacturing the Biopharmaceutical Drug Product -- Complex Process-Related Impurity Profiles -- Seemingly Endless Biomolecular Structural Variants -- Indispensable Potency (Biological Activity) -- Biopharmaceutical Critical Quality Attributes -- The Art of Setting Biopharmaceutical Specifications – Release and Shelf-Life -- The Challenge of Demonstrating Biopharmaceutical Product Comparability -- Strategic CMC-Focused Interactions with Regulatory Authorities. |
| Record Nr. | UNINA-9910731488803321 |
Geigert John
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Current opinion in pharmacology
| Current opinion in pharmacology |
| Pubbl/distr/stampa | [Oxford, England?], : Elsevier Science, ©2001- |
| Disciplina | 615.105 |
| Soggetto topico |
Pharmacology
Pharmacology - Periodicals Drugs Chemotherapy Biopharmaceutics Pharmaceutical Preparations Drug Therapy Pharmacokinetics Antineoplastic Agents Pharmacologie - Périodiques Pharmacologie Médicaments Chimiothérapie Biopharmacie |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Pharmacy, Therapeutics, & Pharmacology |
| ISSN | 1471-4973 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910333151603321 |
| [Oxford, England?], : Elsevier Science, ©2001- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Current opinion in pharmacology
| Current opinion in pharmacology |
| Pubbl/distr/stampa | [Oxford, England?], : Elsevier Science, ©2001- |
| Disciplina | 615.105 |
| Soggetto topico |
Pharmacology
Pharmacology - Periodicals Drugs Chemotherapy Biopharmaceutics Pharmaceutical Preparations Drug Therapy Pharmacokinetics Antineoplastic Agents Pharmacologie - Périodiques Pharmacologie Médicaments Chimiothérapie Biopharmacie |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Pharmacy, Therapeutics, & Pharmacology |
| ISSN | 1471-4973 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996218692503316 |
| [Oxford, England?], : Elsevier Science, ©2001- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Drug discovery research [[electronic resource] ] : new frontiers in the post-genomic era / / edited by Ziwei Huang
| Drug discovery research [[electronic resource] ] : new frontiers in the post-genomic era / / edited by Ziwei Huang |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (560 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | HuangZiwei <1965-> |
| Soggetto topico |
Drugs - Design
Biopharmaceutics Pharmaceutical chemistry |
| ISBN |
1-280-90025-3
9786610900251 0-470-13186-1 0-470-13185-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Molecular docking and structure-based design / P. Therese Lang ... [et al.] -- Recent advances in drug discovery research using structure-based virtual screening techniques : examples of success for diverse protein targets / Sutapa Ghosh ... [et al.] -- Virtual screening in drug discovery / Malcolm J. McGregor, Zhaowen Luo, and Xuliang Jiang -- Computer-aided drug design / Grace Shiahuy Chen and Ji-Wang Chern -- Focused library design based on hit and target structures : method and application in drug discovery / Weiliang Zhu ... [et al.] --
Beyond natural products : synthetic analogs of bryostatin 1 / Paul A. Wender ... [et al.] -- The promises and pitfalls of small-molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG) / Amanda C. Nottbohm and Paul J. Hergenrother -- Cyclic ADP-ribose analogues with minimal structure : synthesis and calcium-release activity / Lihe Zhang and Andreas H. Guse -- Evaluation of neuroimmunophilin ligands / Junhai Xiao, Aihua Nie, and Song Li -- Chiral drugs and the associated asymmetric synthesis / Jiange Zhang and Guoqiang Lin -- Alpha-helix mimetics in drug discovery / Hang Yin, Gui-In Lee, and Andrew D. Hamilton -- Basic and translational research of chemokine ligands and receptors and development of novel therapeutics / Won-Tak Choi ... [et al.] -- Research progress in protein post-translational modification / Jia Hu, Yanting Guo, and Yanmei Li -- Controlled release of antibiotics encapsulated in nanoporous sol-gel materials with tunable pore parameters / Houping Yin, Laura Zheng, and Yen Wei -- Retinoic acid and arsenic trioxide treatment in acute promyelocytic leukemia : a model of oncoprotein targeted therapy / Jian-Hua Tong, Sai-Juan Chen, and Zhu Chen. 2-chlorodeoxyadenosine (cladribine) : rational development of a novel chemotherapeutic agent / Howard B. Cottam and Dennis A. Carson -- Apoptosis-based drug discovery for cancer / John C. Reed ... [et al.] -- Mechanism-based development of memantine as a therapeutic agent in treating Alzheimer's disease and other neurologic disorders : low-affinity, uncompetitive antagonism with fast off-rate / Huei-Sheng Vincent Chen and Stuart A. Lipton -- Bridging bench to clinic : roles of animal models for post-genomics drug discovery on metabolic diseases / Chi-Wai Wong and Ling Chen -- Stem cell research and applications for human therapies / Prithi Rajan ... [et al.]. |
| Record Nr. | UNINA-9910143576203321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery research [[electronic resource] ] : new frontiers in the post-genomic era / / edited by Ziwei Huang
| Drug discovery research [[electronic resource] ] : new frontiers in the post-genomic era / / edited by Ziwei Huang |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (560 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | HuangZiwei <1965-> |
| Soggetto topico |
Drugs - Design
Biopharmaceutics Pharmaceutical chemistry |
| ISBN |
1-280-90025-3
9786610900251 0-470-13186-1 0-470-13185-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Molecular docking and structure-based design / P. Therese Lang ... [et al.] -- Recent advances in drug discovery research using structure-based virtual screening techniques : examples of success for diverse protein targets / Sutapa Ghosh ... [et al.] -- Virtual screening in drug discovery / Malcolm J. McGregor, Zhaowen Luo, and Xuliang Jiang -- Computer-aided drug design / Grace Shiahuy Chen and Ji-Wang Chern -- Focused library design based on hit and target structures : method and application in drug discovery / Weiliang Zhu ... [et al.] --
Beyond natural products : synthetic analogs of bryostatin 1 / Paul A. Wender ... [et al.] -- The promises and pitfalls of small-molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG) / Amanda C. Nottbohm and Paul J. Hergenrother -- Cyclic ADP-ribose analogues with minimal structure : synthesis and calcium-release activity / Lihe Zhang and Andreas H. Guse -- Evaluation of neuroimmunophilin ligands / Junhai Xiao, Aihua Nie, and Song Li -- Chiral drugs and the associated asymmetric synthesis / Jiange Zhang and Guoqiang Lin -- Alpha-helix mimetics in drug discovery / Hang Yin, Gui-In Lee, and Andrew D. Hamilton -- Basic and translational research of chemokine ligands and receptors and development of novel therapeutics / Won-Tak Choi ... [et al.] -- Research progress in protein post-translational modification / Jia Hu, Yanting Guo, and Yanmei Li -- Controlled release of antibiotics encapsulated in nanoporous sol-gel materials with tunable pore parameters / Houping Yin, Laura Zheng, and Yen Wei -- Retinoic acid and arsenic trioxide treatment in acute promyelocytic leukemia : a model of oncoprotein targeted therapy / Jian-Hua Tong, Sai-Juan Chen, and Zhu Chen. 2-chlorodeoxyadenosine (cladribine) : rational development of a novel chemotherapeutic agent / Howard B. Cottam and Dennis A. Carson -- Apoptosis-based drug discovery for cancer / John C. Reed ... [et al.] -- Mechanism-based development of memantine as a therapeutic agent in treating Alzheimer's disease and other neurologic disorders : low-affinity, uncompetitive antagonism with fast off-rate / Huei-Sheng Vincent Chen and Stuart A. Lipton -- Bridging bench to clinic : roles of animal models for post-genomics drug discovery on metabolic diseases / Chi-Wai Wong and Ling Chen -- Stem cell research and applications for human therapies / Prithi Rajan ... [et al.]. |
| Record Nr. | UNINA-9910830812503321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery research [[electronic resource] ] : new frontiers in the post-genomic era / / edited by Ziwei Huang
| Drug discovery research [[electronic resource] ] : new frontiers in the post-genomic era / / edited by Ziwei Huang |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (560 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | HuangZiwei <1965-> |
| Soggetto topico |
Drugs - Design
Biopharmaceutics Pharmaceutical chemistry |
| ISBN |
1-280-90025-3
9786610900251 0-470-13186-1 0-470-13185-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Molecular docking and structure-based design / P. Therese Lang ... [et al.] -- Recent advances in drug discovery research using structure-based virtual screening techniques : examples of success for diverse protein targets / Sutapa Ghosh ... [et al.] -- Virtual screening in drug discovery / Malcolm J. McGregor, Zhaowen Luo, and Xuliang Jiang -- Computer-aided drug design / Grace Shiahuy Chen and Ji-Wang Chern -- Focused library design based on hit and target structures : method and application in drug discovery / Weiliang Zhu ... [et al.] --
Beyond natural products : synthetic analogs of bryostatin 1 / Paul A. Wender ... [et al.] -- The promises and pitfalls of small-molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG) / Amanda C. Nottbohm and Paul J. Hergenrother -- Cyclic ADP-ribose analogues with minimal structure : synthesis and calcium-release activity / Lihe Zhang and Andreas H. Guse -- Evaluation of neuroimmunophilin ligands / Junhai Xiao, Aihua Nie, and Song Li -- Chiral drugs and the associated asymmetric synthesis / Jiange Zhang and Guoqiang Lin -- Alpha-helix mimetics in drug discovery / Hang Yin, Gui-In Lee, and Andrew D. Hamilton -- Basic and translational research of chemokine ligands and receptors and development of novel therapeutics / Won-Tak Choi ... [et al.] -- Research progress in protein post-translational modification / Jia Hu, Yanting Guo, and Yanmei Li -- Controlled release of antibiotics encapsulated in nanoporous sol-gel materials with tunable pore parameters / Houping Yin, Laura Zheng, and Yen Wei -- Retinoic acid and arsenic trioxide treatment in acute promyelocytic leukemia : a model of oncoprotein targeted therapy / Jian-Hua Tong, Sai-Juan Chen, and Zhu Chen. 2-chlorodeoxyadenosine (cladribine) : rational development of a novel chemotherapeutic agent / Howard B. Cottam and Dennis A. Carson -- Apoptosis-based drug discovery for cancer / John C. Reed ... [et al.] -- Mechanism-based development of memantine as a therapeutic agent in treating Alzheimer's disease and other neurologic disorders : low-affinity, uncompetitive antagonism with fast off-rate / Huei-Sheng Vincent Chen and Stuart A. Lipton -- Bridging bench to clinic : roles of animal models for post-genomics drug discovery on metabolic diseases / Chi-Wai Wong and Ling Chen -- Stem cell research and applications for human therapies / Prithi Rajan ... [et al.]. |
| Record Nr. | UNINA-9910841329303321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery today Therapeutic strategies
| Drug discovery today Therapeutic strategies |
| Pubbl/distr/stampa | [Amsterdam] ; ; [New York, NY], : Elsevier, ©2004-[2013] |
| Descrizione fisica | 1 online resource |
| Disciplina | 338.4/76151 |
| Soggetto topico |
Pharmaceutical industry
Drug development Drugs - Design Biopharmaceutics Clinical pharmacology Drug Therapy Drug Design |
| Soggetto genere / forma | Periodicals. |
| Soggetto non controllato | Industries |
| ISSN | 1740-6773 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Therapeutic strategies |
| Record Nr. | UNISA-996216406303316 |
| [Amsterdam] ; ; [New York, NY], : Elsevier, ©2004-[2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Drug discovery today Therapeutic strategies
| Drug discovery today Therapeutic strategies |
| Pubbl/distr/stampa | [Amsterdam] ; ; [New York, NY], : Elsevier, ©2004-[2013] |
| Descrizione fisica | 1 online resource |
| Disciplina | 338.4/76151 |
| Soggetto topico |
Pharmaceutical industry
Drug development Drugs - Design Biopharmaceutics Clinical pharmacology Drug Therapy Drug Design |
| Soggetto genere / forma | Periodicals. |
| Soggetto non controllato | Industries |
| ISSN | 1740-6773 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Therapeutic strategies |
| Record Nr. | UNINA-9910143542503321 |
| [Amsterdam] ; ; [New York, NY], : Elsevier, ©2004-[2013] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug disposition and pharmacokinetics : principles and applications for medicine, toxicology and biotechnology / / Stephen H. Curry and Robin Whelpton
| Drug disposition and pharmacokinetics : principles and applications for medicine, toxicology and biotechnology / / Stephen H. Curry and Robin Whelpton |
| Autore | Curry Stephen H. |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, , [2022] |
| Descrizione fisica | 1 online resource (480 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Pharmacokinetics
Biopharmaceutics Drugs - Metabolism |
| ISBN |
9781119589198
9781119588436 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Setting the Scene: Concepts, Nature of Drugs, and Quality of Results -- 1.1 Introduction -- 1.2 Concepts and terminology: disposition and pharmacokinetics -- 1.3 Pharmacokinetic parameters -- 1.3.1 Half-life -- 1.3.2 Clearance and apparent volume of distribution -- 1.3.3 Area under the plasma concentration-time curve -- 1.3.4 Apparent oral clearance -- 1.4 Time-concentration-effect relationships -- 1.5 Properties of drugs and xenobiotics -- 1.6 Quality of the data -- 1.6.1 Quantification of analyte concentrations -- 1.6.2 Timing of samples -- 1.6.3 Quality control and method validation -- 1.7 References -- Chapter 2 Drug Disposition and Fate -- 2.1 Introduction -- 2.2 Transport proteins -- 2.3 Absorption -- 2.3.1 Gastrointestinal tract -- 2.3.2 Drug transfer across the gastrointestinal tract -- 2.3.3 Other mucus membranes -- 2.3.4 Skeletal muscle -- 2.3.5 Skin -- 2.3.6 Absorption of macromolecules and nanoparticles -- 2.4 Distribution -- 2.4.1 Mechanisms of sequestration -- 2.4.2 Assessing the extent and location of distribution -- 2.4.3 Kinetics of distribution -- 2.5 Metabolism -- 2.5.1 Phase 1 metabolism -- 2.5.2 Phase 2 conjugations -- 2.5.3 Metabolism by microbiota -- 2.6 Excretion -- 2.6.1 Urine -- 2.6.2 Biliary excretion -- 2.6.3 Expired air -- 2.6.4 Saliva -- 2.6.5 Stomach and intestine -- 2.6.6 Breast milk -- 2.6.7 Other routes of excretion -- 2.6.8 Cycling processes -- 2.7 References -- Chapter 3 Pharmacokinetic Modelling -- 3.1 Introduction -- 3.2 Fundamental concepts -- 3.2.1 Apparent volume of distribution -- 3.2.2 Clearance -- 3.3 Elimination -- 3.3.1 First-order elimination -- 3.3.2 Non-linear elimination -- 3.4 Intravenous infusions -- 3.4.1 Single-compartment model with first-order elimination -- 3.4.2 Two-compartment model with first-order elimination.
3.5 First-order input and elimination -- 3.5.1 Absorption -- 3.5.2 Multiple dosing -- 3.6 Areas under the plasma concentration-time curve: trapezoidal method -- 3.7 Statistical moment theory -- 3.7.1 Estimating AUMC -- 3.8 Bioavailability and bioequivalence -- 3.8.1 Non-linear kinetics -- 3.8.2 Effect of systemic availability on plasma concentration-time curves -- 3.8.3 Factors affecting bioavailability -- 3.8.4 Bioequivalence -- 3.9 Physiological modelling -- 3.9.1 Practical considerations -- 3.10 Population kinetics -- 3.11 References -- Chapter 4 Pharmacokinetics of Metabolism and Excretion -- 4.1 Introduction -- 4.2 Metabolite kinetics -- 4.2.1 Basic concepts -- 4.2.2 Fraction of metabolite formed -- 4.2.3 More complex situations -- 4.2.4 Effect of pre-systemic metabolism -- 4.2.5 Interconversion of drug and metabolite -- 4.2.6 Active metabolites and prodrugs -- 4.2.7 Kinetics of formed and preformed metabolites -- 4.3 Kinetics of urinary excretion -- 4.3.1 Renal clearance -- 4.3.2 Effect of urine flow rate -- 4.3.3 Estimating renal blood flow and glomerular filtration rate -- 4.3.4 Specific drug examples -- 4.4 Excretion in faeces -- 4.5 References -- Chapter 5 Quantitative Pharmacological Relationships -- 5.1 Introduction -- 5.2 Concentration-effect relationships and dose-response curves -- 5.3 Concentration-effect relationships in vivo -- 5.4 Time-Dependent Models -- 5.4.1 Direct link and indirect link models -- 5.4.2 Temporal displacement -- 5.4.3 Inhomogeneity of plasma -- 5.4.4 Effects of unequal distribution in plasma -- 5.4.5 Pharmacokinetic distributional models -- 5.5 PK-PD modelling -- 5.5.1 PK-PD modelling under steady-state conditions -- 5.5.2 Use of effect-compartment models -- 5.5.3 Indirect-response models -- 5.5.4 Disease progression models -- 5.5.5 Time-related changes in pharmacodynamic parameters -- 5.5.6 Schedule dependence. 5.5.7 Basic PK-PD versus system PK-PD -- 5.6 References -- Chapter 6 Predictive Pharmacokinetics -- 6.1 Introduction -- 6.2 Physiochemical properties -- 6.2.1 Druggability -- 6.2.2 Drug-likeness -- 6.2.3 Dissolution studies -- 6.3 Metabolic stability -- 6.3.1 Microsomal intrinsic clearance -- 6.3.2 Hepatocytes -- 6.3.3 Recombinant human cytochromes -- 6.4 Plasma protein and tissue binding and blood/plasma ratios -- 6.4.1 Plasma protein binding -- 6.4.2 Erythrocyte concentrations -- 6.5 Hepatic clearance -- 6.5.1 Hepatic intrinsic clearance -- 6.5.2 Effect of plasma protein binding on elimination kinetics -- 6.6 Experimental methods of assessing transfer across biological membranes -- 6.6.1 Cell culture -- 6.6.2 Parallel artificial membrane permeability assay -- 6.6.3 Ussing chambers -- 6.6.4 Intestinal sacs -- 6.6.5 In vivo/in situ studies -- 6.7 Allometric scaling -- 6.7.1 Refinements to allometric scaling -- 6.7.2 Practical aspects of allometry -- 6.7.3 Method of Wajima -- 6.8 In silico predictions and PBPK modelling -- 6.9 Microdosing studies -- 6.10 Translational science -- 6.11 References -- Chapter 7 Disposition of Peptides and Other Biological Molecules -- 7.1 Introduction -- 7.2 Chemical aspects -- 7.2.1 PEGylation -- 7.3 Assay methods -- 7.4 Pharmacokinetics -- 7.4.1 Administration and dosage -- 7.4.2 Bioequivalence and biosimilarity -- 7.4.3 Distribution -- 7.4.4 Metabolism -- 7.4.5 Excretion -- 7.5 Plasma kinetics and pharmacodynamics -- 7.6 Examples of particular interest -- 7.6.1 Botulinum toxins -- 7.6.2 Cholecystokinins -- 7.6.3 Ciclosporin -- 7.6.4 Cocaine hydrolases -- 7.6.5 Erythropoietin -- 7.6.6 Heparin -- 7.6.7 Mipomersen -- 7.6.8 Somatotropin -- 7.6.9 Vasopressin and desmopressin -- 7.7 References -- Chapter 8 Monoclonal Antibodies -- 8.1 Introduction -- 8.2 Nomenclature -- 8.3 Circulation of monoclonal antibodies. 8.3.1 Convection -- 8.3.2 Neonatal Fc receptor -- 8.3.3 Binding to soluble target antigens -- 8.4 Pharmaceutical and DMPK aspects -- 8.4.1 Routes of administration -- 8.4.2 Distribution and apparent volume of distribution -- 8.4.3 Metabolism and excretion -- 8.4.4 Pharmacokinetics -- 8.4.5 Individual and population pharmacokinetics -- 8.5 Development of orally administered monoclonal antibodies -- 8.6 Optimizing pharmacokinetic and pharmacodynamic properties -- 8.7 Two highlighted early and durable examples -- 8.7.1 Trastuzumab -- 8.7.2 Adalimumab -- 8.8 PBPK modelling -- 8.9 Antibody-drug conjugates -- 8.9.1 Payloads -- 8.9.2 Linkers -- 8.9.3 Bystander killing -- 8.9.4 Disposition and pharmacokinetics -- 8.10 References -- Chapter 9 Drug Metabolism and Pharmacokinetics in Veterinary Sciences -- 9.1 Introduction -- 9.2 Areas of practice -- 9.2.1 Companion animal medicine -- 9.2.2 Treatment of animals of commerce -- 9.2.3 Zoos and wildlife preserves -- 9.2.4 Laboratory animal medicine -- 9.3 Scientific approach including allometric scaling -- 9.4 Information organized by pharmacokinetic processes -- 9.4.1 Administration -- 9.4.2 Absorption -- 9.4.3 Tissue distribution -- 9.4.4 Plasma protein binding and transporters -- 9.4.5 Metabolism -- 9.4.6 Excretion -- 9.5 Information organized by species and drugs -- 9.5.1 Mammals -- 9.5.2 Fish -- 9.6 Some drugs unique to veterinary science -- 9.7 Accidental exposure: toxicology - drugs used by humans that are dangerous to animals -- 9.7.1 Paracetamol in cats -- 9.7.2 Xanthines: chocolate in dogs -- 9.8 Residue analysis -- 9.9 References -- Chapter 10 Factors Affecting Plasma Concentrations: Consideration of Special Populations -- 10.1 Introduction -- 10.2 Pharmaceutical factors -- 10.3 Weight and obesity -- 10.3.1 Effects of obesity on pharmacokinetics -- 10.3.2 Dose adjustment in obesity. 10.3.3 Oral contraceptives -- 10.3.4 Gastric bypass surgery -- 10.3.5 Psychiatric patients -- 10.4 Food, diet, and nutrition -- 10.4.1 Diet and nutrition -- 10.5 Time of day -- 10.5.1 Circadian rhythms -- 10.5.2 Absorption -- 10.5.3 The liver -- 10.5.4 The kidneys -- 10.5.5 Intravenous and other injected doses -- 10.5.6 Pharmacodynamics -- 10.6 Posture and exercise -- 10.6.1 Exercise -- 10.7 Smoking -- 10.8 References -- Chapter 11 Pharmacogenetics, Pharmacogenomics, and Precision Medicine -- 11.1 Introduction -- 11.1.1 Terminology -- 11.2 Methods for the study of pharmacogenetics -- 11.2.1 Studies in twins -- 11.2.2 Phenotyping and genotyping -- 11.3 N-Acetyltransferase -- 11.3.1 Isoniazid -- 11.3.2 Sulfonamides -- 11.3.3 Other drugs -- 11.3.4 Genotyping N-acetyltransferase -- 11.4 Plasma cholinesterase -- 11.4.1 Suxamethonium -- 11.5 Carboxylesterases -- 11.6 Cytochrome P450 polymorphisms -- 11.6.1 Cytochrome 2D6 -- 11.6.2 Cytochrome 2C9 -- 11.6.3 Cytochrome 2C19 -- 11.6.4 Cytochromes 3A4/5 -- 11.6.5 Other cytochrome P450 polymorphisms -- 11.7 Glucose-6-phosphate dehydrogenase -- 11.7.1 Glucose-6-phosphate dehydrogenase deficiency -- 11.7.2 Triggering -- 11.7.3 Effects on pharmacokinetics -- 11.8 Alcohol dehydrogenase and acetaldehyde dehydrogenase -- 11.9 Thiopurine methyltransferase -- 11.10 Phase 2 enzymes -- 11.10.1 UDP-glucuronosyltransferases -- 11.10.2 Sulfotransferases -- 11.10.3 Glutathione transferases -- 11.11 Transporters -- 11.12 Pharmacodynamic differences -- 11.13 Ethnicity -- 11.14 Personalized medicine -- 11.15 References -- Chapter 12 Effects of Sex and Pregnancy on Drug Disposition and Pharmacokinetics -- 12.1 Introduction -- 12.1.1 Studies in animals -- 12.2 Effect of sex on human drug disposition and pharmacokinetics -- 12.2.1 Absorption and bioavailability -- 12.2.2 Distribution -- 12.2.3 Metabolism -- 12.2.4 Excretion. 12.2.5 Effects. |
| Record Nr. | UNINA-9910642949103321 |
|
Curry Stephen H.
|
||
| Hoboken, New Jersey : , : John Wiley & Sons, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Biopharmaceutics
(106)
- Pharmacology (21)
- Pharmaceutical chemistry (19)
- Drugs - Design (16)
- Drug development (14)